Impact of BNT162b2 mRNA anti-SARS-CoV-2 vaccine on interferon-alpha production by plasmacytoid dendritic cells and autoreactive T cells in patients with systemic lupus erythematosus: The COVALUS project

Mageau A, Tchen J, Ferré VM, Nicaise-Roland P, Descamps D, Delory N, François C, Mendes C, Papo T, Goulenok T, Charles N, Sacré K. J Autoimmun. 2022 Dec 19;134:102987. doi: 10.1016/j.jaut.2022.102987. Online ahead of print. PMID: 36563528

Objective: To evaluate the specific response of SLE patients to BNT162b2 vaccination and its impact on autoimmunity defined as in vivo production of interferon-alpha (IFNα) by plasmacytoid dendritic cells (pDCs) and autoreactive immune responses.

Methods: Our prospective study included SLE patients and healthy volunteers (HV) who received 2 doses of BNT162b2 vaccine 4 weeks apart. Subjects under immunosuppressive drugs or with evidence of prior COVID-19 were excluded. IgG anti-Spike SARS-CoV-2 (anti-S) antibodies, anti-S specific-B cells, anti-S specific T cells, in vivo INF-α production by pDCs, activation marker expression by pDCs and autoreactive anti-nuclear T cells were quantified before first injection, before second injection, and 3 and 6 months after first injection.

Results: Vaccinated SLE patients produced significantly lower IgG antibodies and specific B cells against SARS-CoV-2 as compared to HV. In contrast, anti-S T cell response did not significantly differ between SLE patients and HV. Following vaccination, the surface expression of HLA-DR and CD86 and the in vivo production of IFNα by pDCs significantly increased in SLE patients. The boosted expression of HLA-DR on pDCs induced by BNT162b2 vaccine correlated with the overall immune responses against SARS-CoV-2 (anti-S antibodies: r = 0.27 [0.05-0.46], p = 0.02; anti-S B cells: r = 0.19 [-0.03-0.39], p = 0.09); anti-S T cells: r = 0.28 [0.05-0.47], p = 0.016). Eventually, anti-SARS-CoV-2 vaccination was associated with an overall decrease of autoreactive T cells (slope = – 0.00067, p = 0.015).

Conclusion: BNT162b2 vaccine induces a transient in vivo activation of pDCs in SLE that contributes to the immune responses against SARS-CoV-2. Unexpectedly BNT162b2 vaccine also dampens the pool of circulating autoreactive T cells, suggesting that vaccination may have a beneficial impact on SLE disease.


Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.

Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M. J Hepatol. 2022 Jul 20:S0168-8278(22)02942-7. doi: 10.1016/j.jhep.2022.07.008. Online ahead of print. PMID: 35868584

The COVID-19 pandemic has presented a serious challenge to the hepatology community, particularly healthcare professionals and patients. While the rapid development of safe and effective vaccines and treatments has improved the clinical landscape, the emergence of the omicron variant has presented new challenges. Thus, it is timely that the European Association for the Study of the Liver provides a summary of the latest data on the impact of COVID-19 on the liver and issues guidance on the care of patients with chronic liver disease, hepatobiliary cancer, and previous liver transplantation, as the world continues to deal with the consequences of the COVID-19 pandemic.


Baiges A, Cerda E, Amicone C, Téllez L, Alvarado-Tapias E, Puente A, Fortea JI, Llop E, Rocha F, Orts L, Ros-Fargas O, Vizcarra P, Zekrini K, Lounes OA, Touati G, Jiménez-Esquivel N, Serrano MJ, Falgà A, Magaz M, Olivas P, Betancourt F, Perez-Campuzano V, Turon F, Payancé A, Goria O, Rautou PE, Hernández-Gea V, Villanueva C, Albillos A, Plessier A, García-Pagán JC. Clin Gastroenterol Hepatol. 2022 Jul;20(7):1525-1533.e5. doi: 10.1016/j.cgh.2021.12.032. Epub 2021 Dec 27. PMID: 34968728

Vascular liver diseases (VLDs) are represented mainly by portosinusoidal vascular disease (PSVD), noncirrhotic splanchnic vein thrombosis (SVT), and Budd Chiari syndrome (BCS). It is unknown whether patients with VLDs constitute a high-risk population for complications and greater coronavirus disease 2019 (COVID-19)-related mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our objective was to assess the prevalence and severity of SARS-CoV-2 infection among patients with VLDs, as well as to assess its impact on hepatic decompensation and survival.

Systemic lupus erythematosus flare following SARS-CoV2 infection: the implication of IFNα and anti-IFNα autoantibodies.
Mageau A, Nicaise Roland P, Goulenok T, Farkh C, Charles N, Sacre K. Clin Exp Rheumatol. 2022 Feb 16.

The involvement of type 1 interferon (IFN) and anti-type 1 IFN antibodies (Ab) in the pathophysiology of Systemic Lupus Erythematosus (SLE) and in the immune response during COVID-19 raises the concern of lupus flares induced by the SARS-CoV-2 infection. We report here the case of a patient in whom we were able to monitor the level of IFNα, anti-IFNα Ab and anti-DNA Ab before, during and after infection with COVID-19. The clinical evolution compared with the evolution of these immunological markers suggests a direct link between the viral infection, the drop in the level of anti-IFNα Ab and the lupus flare which followed.  

Tiphaine Goulenok, Chrystelle Francois, Céline Mendes, Fatima Farhi, Jean-Francois Alexandra, Diane Rouzaud, Thomas Papo, Karim Sacre. J Rheumatol. 2021 Oct 15;jrheum.210534. doi: 10.3899/jrheum.210534.
Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors.

Motiejunaite J, Balagny P, Arnoult F, Mangin L, Bancal C, Vidal-Petiot E, Flamant M, Jondeau G, Cohen-Solal A, d’Ortho MP, Frija-Masson J. Eur Respir J. 2021 Aug 26;58(2):2101578. doi: 10.1183/13993003.01578-2021. PMID: 34385265
Residual ground glass opacities three months after Covid-19 pneumonia correlate to alteration of respiratory function: The post Covid M3 study.

Frija-Masson J, Debray MP, Boussouar S, Khalil A, Bancal C, Motiejunaite J, Galarza-Jimenez MA, Benzaquen H, Penaud D, Laveneziana P, Malrin R, Redheuil A, Donciu V, Lucidarme O, Taillé C, Guerder A, Arnoult F, Vidal-Petiot E, Flamant M, Similowski T, Morelot-Panzini C, Faure M, Lescure FX, Straus C, d’Ortho MP, Gonzalez-Bermejo J. Respir Med. 2021 Aug;184:106435. doi: 10.1016/j.rmed.2021.106435. PMID: 34020126
Time of bariatric surgery and hospitalization for SARS-Cov2: a Nationwide study
Poghosyan T , Rives-Lange C, Carette C, Girardeau Y ,Jannot AS , Czernichow S. Obes Surg. 2021 Aug;31(8):3893-3895. doi: 10.1007/s11695-021-05449-z


Renin-angiotensin system blockers and COVID-19.
Vidal-Petiot E, Gault N.  BMC Med. 2021;19(1):136. Published 2021 Jun 4. doi:10.1186/s12916-021-02012-6


SARS-CoV-2 infection among inpatients with systemic lupus erythematosus in France: a nationwide epidemiological study.
Mageau A, Aldebert G, Van Gysel D, Papo T, Timsit JF, Sacre K. Ann Rheum Dis. 2021 Mar 16:annrheumdis-2021-220010. doi: 10.1136/annrheumdis-2021-220010.


The Good Treatment, the Bad Virus, and the Ugly Inflammation: Pathophysiology of Kidney Involvement During COVID-19.
Le Stang MB, Desenclos J, Flamant M, Chousterman BG, Tabibzadeh N. Front Physiol. 2021 Mar 11;12:613019. doi: 10.3389/fphys.2021.613019. eCollection 2021. PMID: 33776785


Chronic use of Renin-Angiotensin-Aldosterone-System blockers and mortality in COVID-19: a multicenter prospective cohort and literature review.
Gault N, Esposito-Farese M, Revest M, Inamo J, Cabie A, Polard É, Hulot JS, Ghosn J, Chirouze C, Deconinck L, Diehl JL, Poissy J, Epaulard O, Lefèvre B, Piroth L, de Montmollin E, Oziol E, Etienne M, Laouenan C, Rossignol P, Costagliola D, Vidal-Petiot E; French-Covid cohort investigators and study group. Fundam Clin Pharmacol. 2021 Apr 20. doi: 10.1111/fcp.12683. Online ahead of print. PMID: 33876439


Arterial Thrombotic Events in Adult Inpatients With COVID-19.
Fournier M, Faille D, Dossier A, Mageau A, Nicaise Roland P, Ajzenberg N, Borie R, Bouadma L, Bunel V, Castier Y, Choquet C, Crestani B, Daugas E, Deconinck L, Descamps D, Descamps V, Dieudé P, Ducrocq G, Faucher N, Goulenok T, Guidoux C, Khalil A, Lavallée P, Lescure FX, Lortat-Jacob B, Mal H, Mutuon P, Pellenc Q, Steg PG, Taille C, Timsit JF, Yazdanpanah Y, Papo T, Sacré K. Mayo Clin Proc. 2021 Feb;96(2):295-303. doi: 10.1016/j.mayocp.2020.11.018. Epub 2020 Nov 27. PMID: 33549252


Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity.
Flament H, Rouland M, Beaudoin L, Toubal A, Bertrand L, Lebourgeois S, Rousseau C, Soulard P, Gouda Z, Cagninacci L, Monteiro AC, Hurtado-Nedelec M, Luce S, Bailly K, Andrieu M, Saintpierre B, Letourneur F, Jouan Y, Si-Tahar M, Baranek T, Paget C, Boitard C, Vallet-Pichard A, Gautier JF, Ajzenberg N, Terrier B, Pène F, Ghosn J, Lescure X, Yazdanpanah Y, Visseaux B, Descamps D, Timsit JF, Monteiro RC, Lehuen A. Nat Immunol. 2021 Feb 2. doi: 10.1038/s41590-021-00870-z. Online ahead of print. PMID: 33531712


Impact of the first Covid-19 outbreak on liver transplantation activity in France: A snapshot.
Turco C, Lim C, Soubrane O, Malaquin G, Kerbaul F, Bastien O, Conti F, Scatton O. Clin Res Hepatol Gastroenterol. 2020 Nov 8:101560. doi: 10.1016/j.clinre.2020.10.005. Online ahead of print. PMID: 33176991


Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area.
Amaddeo G, Brustia R, Allaire M, Lequoy M, Hollande C, Regnault H, Blaise L, Ganne-Carrié N, Séror O, Larrey E, Lim C, Scatton O, El Mouhadi S, Ozenne V, Paye F, Balladur P, Dohan A, Massault PP, Pol S, Burgio MD, Vilgrain V, Sepulveda A, Cauchy F, Luciani A, Sommacale D, Leroy V, Roudot-Thoraval F, Bouattour M, Nault JC; Paris Liver Cancer Group. JHEP Rep. 2021 Feb;3(1):100199. doi: 10.1016/j.jhepr.2020.100199. Epub 2020 Dec 22. PMID: 33163949


Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment.
Lahens A, Mullaert J, Gressens S, Gault N, Flamant M, Deconinck L, Joly V, Yazdanpanah Y, Lescure FX, Vidal-Petiot E. J Hypertens. 2021 Feb 1;39(2):367-375. doi: 10.1097/HJH.0000000000002658. PMID: 33021511


Lipoprotein concentrations over time in the intensive care unit COVID-19 patients: Results from the ApoCOVID study.
Tanaka S, De Tymowski C, Assadi M, Zappella N, Jean-Baptiste S, Robert T, Peoc’h K, Lortat-Jacob B, Fontaine L, Bouzid D, Tran-Dinh A, Tashk P, Meilhac O, Montravers P. PLoS One. 2020 Sep 24;15(9):e0239573. doi: 10.1371/journal.pone.0239573. eCollection 2020. PMID: 32970772


Efficacy of Chest CT for COVID-19 Pneumonia Diagnosis in France.
Herpe G, Lederlin M, Naudin M, Ohana M, Chaumoitre K, Gregory J, Vilgrain V, Freitag CA, De Margerie-Mellon C, Flory V, Ludwig M, Mondot L, Fitton I, Jacquier ARR, Ardilouze P, Petit I, Gervaise A, Bayle O, Crombe A, Mekuko Sokeng M, Thomas C, Henry G, Bliah V, Le Tat T, Guillot MS, Gendrin P, Garetier M, Bertolle E, Montagne C, Langlet B, Kalaaji A, Kayayan H, Desmots F, Dhaene B, Saulnier PJ, Guillevin R, Bartoli JM, Beregi JP, Tasu JP. Radiology. 2021 Feb;298(2):E81-E87. doi: 10.1148/radiol.2020202568. Epub 2020 Sep 1. PMID: 32870139


Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic.
Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. JHEP Rep. 2020 Oct;2(5):100169. doi: 10.1016/j.jhepr.2020.100169. Epub 2020 Aug 4. PMID: 32835190


Extension of COVID-19 pulmonary parenchyma lesions based on real-life visual assessment on initial chest CT is an independent predictor of poor patient outcome.
Grégory J, Raynaud L, Galy A, Corre F, Bijot JC, Nguyen Y, Vilgrain V. Infect Dis (Lond). 2020 Nov;52(11):838-840. doi: 10.1080/23744235.2020.1792544. Epub 2020 Jul 13. PMID: 32657190


No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.
Biquard L, Valla D, Rautou PE. J Hepatol. 2020 Sep;73(3):717-718. doi: 10.1016/j.jhep.2020.04.035. Epub 2020 Apr 30. PMID: 32360995